Study - Enrolling
Atopic Dermatitis Clinical Trials
Living with eczema can be exhausting. Join this Atopic Dermatitis research study in Arizona and help shape better treatment options for people like you.
About this study
Physician Research Group (PRG) is conducting a Phase 3 study to test an investigational treatment for moderate-to-severe atopic dermatitis. The study is recruiting in Arizona for people 12 and older. Researchers will compare it with a placebo, track changes in symptoms and skin severity, and monitor safety. The main assessment happens at Week 24 of participation.
Who may be able to take part?
You may qualify for this Eczema clinical study in Arizona if you are 12 years or older and have a confirmed diagnosis of moderate-to-severe atopic dermatitis with a certain level of skin involvement. A member of the study team reviews every eligibility requirement with you during screening, so you know exactly where you stand.
What participation may involve?
After a screening visit, you are randomly assigned to receive the study treatment or a placebo. Neither you nor the study team knows during the blinded portion. You attend regular visits for skin assessments, lab work, and symptom check-ins, and you track your itch and flares between visits. Your safety is monitored closely by the Physician Research Group (PRG) team.
Questions to ask the study team
Before you join any Atopic Dermatitis clinical trials, it helps to ask. Bring these questions to our Physician Research Group (PRG) study team:
How long will I be in the study, and how many visits?
What are the possible risks, side effects, and benefits of joining this study?
Will I keep seeing my own doctor, and can I leave the study whenever I choose?
Study at a glance
Study Status
Recruiting
Age
12 years or older
Location
Arizona
We're Here to Help!
Thinking about joining a research study but not sure where to start? We're happy to answer your questions, walk you through the process, and help you explore whether a study is right for you.
Frequently Asked Questions
-
The study is a Phase 3 clinical trial evaluating rezpegaldesleukin as a potential Atopic Dermatitis treatment option for people ages 12 and older with moderate to severe symptoms. The study compares the study drug against a placebo to measure safety and effectiveness over time.
-
Eligibility generally includes people ages 12 and older with a confirmed diagnosis of moderate to severe atopic dermatitis, along with a certain level of skin involvement. A member of the study team reviews full eligibility criteria during screening.
-
This study is currently recruiting participants at sites across Arizona. Reach out to the study team to check nearby locations, review eligibility, and learn what participation involves before enrolling.